We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+4.39%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.25B
AUM Growth
-$51.8M
Cap. Flow
+$301K
Cap. Flow %
0.02%
Top 10 Hldgs %
77.76%
Holding
39
New
4
Increased
7
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$13.6M
2
IMVT icon
Immunovant
IMVT
+$13.4M
3
EPIX
ESSA Pharma
EPIX
+$7.36M
4
MTEM
Molecular Templates, Inc.
MTEM
+$6.22M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$4.67M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$18.9M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$14.2M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.21M
4
CRDF icon
Cardiff Oncology
CRDF
+$3.34M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$1.66M

Sector Composition

Rank Sector Weight
1 Healthcare 98.78%
2 Miscellaneous 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.13B
$305M 24.46%
10,542,790
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$723M
$219M 17.56%
5,827,415
– –
PASG icon
3
Passage Bio
PASG
$13.9M
$87.6M 7.02%
250,461
– –
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.08B
$70.7M 5.67%
3,566,912
– –
KRYS icon
5
Krystal Biotech
KRYS
$10.6B
$69M 5.53%
895,000
– –
TARS icon
6
Tarsus Pharmaceuticals
TARS
$3.16B
$61.8M 4.96%
1,917,157
– –
PCVX icon
7
Vaxcyte
PCVX
$9.1B
$45.6M 3.66%
2,309,554
– –
IOVA icon
8
Iovance Biotherapeutics
IOVA
$3.74B
$41.6M 3.33%
1,312,999
– –
TBIO
9
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$36M 2.89%
2,182,789
– –
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
$33.4M 2.68%
3,123,107
+70,000
+2% +$866K
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.8B
$32.1M 2.57%
1,435,045
+30,000
+2% +$678K
ALPN
12
DELISTED
Alpine Immune Sciences Inc
ALPN
$27.3M 2.19%
2,571,450
– –
STRO icon
13
Sutro Biopharma
STRO
$353M
$22.8M 1.83%
100,142
– –
ANAB icon
14
AnaptysBio
ANAB
$1.7B
$19.4M 1.56%
899,700
– –
ACRS icon
15
Aclaris Therapeutics
ACRS
$907M
$17.5M 1.41%
+696,000
New +$13.6M
MTEM
16
DELISTED
Molecular Templates, Inc.
MTEM
$17.3M 1.39%
91,603
+35,476
+63% +$6.22M
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$15.7M 1.26%
2,544,500
+50,000
+2% +$304K
FLACU
18
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$15.3M 1.22%
1,501,000
– –
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
$14.2M 1.14%
143,703
– –
RGNX icon
20
Regenxbio
RGNX
$619M
$12M 0.96%
351,954
+10,000
+3% +$426K
GRTS
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$9.72M 0.78%
1,030,878
-1,030,880
-50% -$14.2M
APTX
22
DELISTED
Aptinyx Inc. Common Stock
APTX
$9.57M 0.77%
3,190,079
– –
EPIX
23
DELISTED
ESSA Pharma
EPIX
$9.2M 0.74%
+316,616
New +$7.36M
IMVT icon
24
Immunovant
IMVT
$9.05B
$8.15M 0.65%
+508,000
New +$13.4M
SRRK icon
25
Scholar Rock
SRRK
$7.22B
$7.9M 0.63%
156,000
+2,500
+2% +$138K
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q1 2021 Portfolio in Review

As of Q1 2021, Frazier Management held 39 positions worth $1.25B, down 4% from $1.3B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Frazier Management's Q1 2021 filing shows 4 new, 7 increased, 2 reduced and 4 closed positions. Its largest new stake was Aclaris Therapeutics: 696,000 shares worth $17.5M. The largest sale was Collegium Pharmaceutical, an estimated $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • Frazier Management's largest Q1 2021 buy was Aclaris Therapeutics: 696,000 shares worth $17.5M.
  • Frazier Management added most to Molecular Templates, Inc. in Q1 2021, an estimated $6.22M increase.
  • Frazier Management's biggest Q1 2021 reduction was Gritstone bio, Inc. Common Stock, cutting an estimated $14.2M.
  • Frazier Management fully exited Collegium Pharmaceutical in Q1 2021, selling an estimated $18.9M.
  • Frazier Management's ten largest holdings make up 78% of its $1.25B portfolio in Q1 2021.
  • Frazier Management opened 4 new positions and closed 4 in Q1 2021.
  • Frazier Management's portfolio value fell 4% quarter-over-quarter to $1.25B.

Based on Frazier Management's 13F filing for Q1 2021, filed 12 May 2021.